Comparison · NCT02006342-0bd7ac77
Insulin Glargine Plus Regular Insulin vs Control - Regular Insulin: Number of Participants Who Developed Hypoglycemia
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Insulin Glargine Plus Regular Insulin vs Control - Regular Insulin: Number of Participants Who Developed Hypoglycemia. Trial comparisons, record NCT02006342-0bd7ac77. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02006342-0bd7ac77
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.1 | 0.0279 | 0.301 | wilson | |
| Risk in group 2 | 0.15 | 0.0524 | 0.36 | wilson | |
| Risk difference, group 1 minus group 2 | -0.05 | -0.272 | 0.173 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.667 | 0.124 | 3.57 | log | |
| Odds ratio, group 1 over group 2 | 0.63 | 0.0934 | 4.24 | log | |
| Number needed to treat, for one fewer participant with the outcome on Insulin Glargine Plus Regular Insulin than on Control - Regular Insulin | 20 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Insulin Glargine Plus Regular Insulin | Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring, with the addition of subcutaneous Insulin Glargine within 2 hours of diagnosis.~Insulin Glargine~Regular Insulin | 2 | 20 | OG000 |
| Group 2 | Control - Regular Insulin | Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring.~Regular Insulin | 3 | 20 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Who Developed Hypoglycemia
- Description
To determine whether it is safe to administer both IV and subcutaneous insulin, it is important to assure that patient's glucose does not drop to critically low level and lead to adverse events. Hypoglycemia was defined as less than or equal to 60mg/dL during 24 hours after anion gap closure.~Anion Gap is a measure of acidosis that results from decompensated Diabetes Mellitus. Acidosis is the result of the body being unable to utilize glucose for energy production and instead uses fatty acid metabolism resulting in ketone formation. Anion Gap is a surrogate measure for the level of ketones resulting in the excess acid production.
- Time frame
- Participants monitored during the 24 hours after anion gap closure
- Population
- While one participant in the glargine group did not receive glargine, all who were enrolled were analyzed (intention to treat analysis).
Source ClinicalTrials.gov
Trial
- Title
- Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis
- NCT number
- NCT02006342
- Phases
- NA
- Conditions
- Diabetic Ketoacidosis
- Interventions
- Insulin Glargine, Regular Insulin
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Results first posted
- 2017-05-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02006342?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02006342-0bd7ac77